GlobeNewswire: Coronado Biosciences Contains the last 10 of 80 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:30:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2013/11/07/587752/10056769/en/Coronado-Biosciences-Announces-Independent-Data-Monitoring-Committee-Recommendation-to-Discontinue-Falk-Phase-2-Trial-of-TSO-in-Crohn-s-Disease.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Announces Independent Data Monitoring Committee Recommendation to Discontinue Falk Phase 2 Trial of TSO in Crohn's Disease2013-11-07T11:30:00Z<![CDATA[BURLINGTON, Mass., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, today announced that it has been informed by Dr. Falk Pharma GmbH (Falk), its development partner, that an Independent Data Monitoring Committee (IDMC) has conducted a second interim analysis of clinical data from approximately 240 patients who have completed 12 weeks of treatment in Falk's Phase 2 clinical trial in Europe evaluating ]]>https://www.globenewswire.com/news-release/2013/11/06/587217/10056423/en/Coronado-Biosciences-Announces-Personnel-Realignment-Including-Appointment-of-Kevin-Horgan-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer2013-11-06T11:30:00Z<![CDATA[BURLINGTON, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the appointment of Kevin Horgan, M.D., as its Chief Medical Officer. Dr. Horgan will oversee the company's clinical development programs and regulatory and medical affairs activities for its lead product candidates, TSO (]]>https://www.globenewswire.com/news-release/2013/11/01/585864/10055700/en/Coronado-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-Ended-September-30-2013.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Reports Financial Results for the Third Quarter Ended September 30, 20132013-11-01T12:00:00Z<![CDATA[BURLINGTON, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the third quarter ended September 30, 2013.]]>https://www.globenewswire.com/news-release/2013/10/14/580190/10052399/en/Coronado-Biosciences-Announces-Top-Line-Results-From-Its-TRUST-I-Phase-2-Clinical-Trial-of-TSO-for-the-Treatment-of-Crohn-s-Disease.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Announces Top-Line Results From Its TRUST-I Phase 2 Clinical Trial of TSO for the Treatment of Crohn's Disease2013-10-14T12:30:00Z<![CDATA[Company to Host Conference Call Today, October 14, 2013 at 9:00AM ET to Discuss Results BURLINGTON, Mass., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, today announced top-line results from TRUST-I, its Phase 2 clinical trial evaluating TSO (]]>https://www.globenewswire.com/news-release/2013/09/12/573041/10048210/en/Coronado-Biosciences-Announces-Initiation-of-Phase-2-Study-Evaluating-TSO-in-Ulcerative-Colitis.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Announces Initiation of Phase 2 Study Evaluating TSO in Ulcerative Colitis2013-09-12T11:30:00Z<![CDATA[BURLINGTON, Mass., Sept. 12, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of a National Institutes of Health (NIH)-sponsored phase 2 study evaluating TSO (]]>https://www.globenewswire.com/news-release/2013/09/03/571011/10047041/en/Coronado-Biosciences-to-Present-at-Upcoming-Healthcare-Investor-Conferences.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences2013-09-03T12:30:00Z<![CDATA[BURLINGTON, Mass., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will present at the following upcoming investor conferences:]]>https://www.globenewswire.com/news-release/2013/08/27/569451/10046140/en/Coronado-Biosciences-to-Participate-in-Citi-s-8th-Annual-Biotech-Conference.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference2013-08-27T12:30:00Z<![CDATA[BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will participate in Citi's 8th Annual Biotech Conference. The conference will be held at the Mandarin Oriental Boston on September 3-4, 2013. The format of the conference will consist of one-on-one meetings and industry panels.]]>https://www.globenewswire.com/news-release/2013/08/20/567949/10045544/en/Coronado-Biosciences-to-Present-at-the-Upcoming-Themes-in-Helminth-Biology-Scientific-Conference.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences to Present at the Upcoming Themes in Helminth Biology Scientific Conference2013-08-20T12:30:00Z<![CDATA[BURLINGTON, Mass., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Karin Hehenberger, Coronado's Executive Vice President of Scientific Affairs, will present at the Themes in Helminth Biology Conference on Friday, August 30, 2013, at 8:30 AM EET. Dr. Hehenberger will also be chairing the Helminths and Type 1 Diabetes panel discussion. The conference will be held in Hydra, Greece on August 28-31, 2013.]]>https://www.globenewswire.com/news-release/2013/08/05/564479/10043295/en/Coronado-Biosciences-Reports-Financial-Results-for-the-Second-Quarter-Ended-June-30-2013.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences Reports Financial Results for the Second Quarter Ended June 30, 20132013-08-05T11:00:00Z<![CDATA[BURLINGTON, Mass., Aug. 5, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for the second quarter ended June 30, 2013.]]>https://www.globenewswire.com/news-release/2013/08/01/563940/10042957/en/Coronado-Biosciences-to-Present-at-Upcoming-Healthcare-Investor-Conferences.html?f=22&fvtc=4&fvtv=14003Coronado Biosciences to Present at Upcoming Healthcare Investor Conferences2013-08-01T12:30:00Z<![CDATA[BURLINGTON, Mass., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will present at the following upcoming investor conferences:]]>